TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39174958

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (50 mJ, 1.5 W/30 Hz, 50% air, 40% water) - Protocol 1 (4 cycles at 2.5 min)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (50 mJ, 1.5 W/30 Hz, 50% air, 40% water) - Protocol 2 (5 cycles at 5 min)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (2 native implants)
Number of subjects: 3
Study: 39175062

Group type: EXPERIMENTAL
Intervention: Spatial repellents (SRs) distributed through a reference channel (study personnel distribution)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Spatial repellents (SRs) distributed through a voucher channel
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Spatial repellents (SRs) distributed through the Village Health Team channel
Number of subjects: 3
Study: 39175082

Group type: EXPERIMENTAL
Intervention: VIDACTIVA intervention (8 sessions over 14 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard care (2 psychoeducation sessions)
Number of subjects: 64
Study: 39175217

Group type: EXPERIMENTAL
Intervention: BI 1291583
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 1291583 with itraconazole
Number of subjects: 0
Study: 39175342

Group type: EXPERIMENTAL
Intervention: Day-2-group (warfarin started on day 2 after CS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Day-5-group (warfarin started on day 5 after CS)
Number of subjects: 114
Study: 39175480

Group type: EXPERIMENTAL
Intervention: CHOPX (CHOP plus targeted agents)
Number of subjects: 96

Group type: COMPARATOR
Intervention: CHOP (control group)
Number of subjects: 96
Study: 39175547

Group type: EXPERIMENTAL
Intervention: Fospropofol disodium (6.5 mg/kg initial bolus, 1.6 mg/kg supplemental as needed)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Propofol (1.5 mg/kg initial bolus, 0.5 mg/kg supplemental as needed)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Fospropofol disodium
Number of subjects: 256

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 256
Study: 39175624

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for 24 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy Aging Education (HE) control intervention
Number of subjects: 25
Study: 39175759

Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 39175843

Group type: EXPERIMENTAL
Intervention: Efavirenz-based ART for 1-7 days prior to randomization
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Postnatal nevirapine +/- zidovudine prophylaxis
Number of subjects: 833
Study: 39175910

Group type: EXPERIMENTAL
Intervention: SBIRT implementation for adolescent AOD use
Number of subjects: 430
Study: 39175923

Group type: EXPERIMENTAL
Intervention: Real-time digital assessment tools
Number of subjects: 0
Study: 39175939

Group type: EXPERIMENTAL
Intervention: 5-SENSE Score
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 5-SENSE Score with auxiliary diagnostic methods
Number of subjects: 200
Study: 39176029

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 62

Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 62
Study: 39176240

Group type: EXPERIMENTAL
Intervention: Add-on low dose Astragalus membranaceus (AM) for 24 weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Add-on high dose Astragalus membranaceus (AM) for 24 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine care for 24 weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Add-on low dose Astragalus membranaceus (AM)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Add-on high dose Astragalus membranaceus (AM)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All groups (low dose AM, high dose AM, routine care)
Number of subjects: 66
Study: 39177285

Group type: EXPERIMENTAL
Intervention: ORIC-101 with nab-paclitaxel
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (taxane-based regimen)
Number of subjects: 83
Study: 39177431

Group type: EXPERIMENTAL
Intervention: Pneumonia patients in PICU
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Pediatric Index of Mortality 3 score
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Drowsiness
Number of subjects: 846
Study: 39177553

Group type: EXPERIMENTAL
Intervention: AccuFFRct
Number of subjects: 339
Study: 39177596

Group type: EXPERIMENTAL
Intervention: Gantenerumab (up to 1,200 mg every 4 weeks)
Number of subjects: 225
Study: 39177931

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor (dapagliflozin) with alpelisib
Number of subjects: 93

Group type: COMPARATOR
Intervention: Alpelisib alone (control)
Number of subjects: 93
Study: 39178000

Group type: EXPERIMENTAL
Intervention: Tourniquet group
Number of subjects: 59

Group type: COMPARATOR
Intervention: No tourniquet group
Number of subjects: 59
Study: 39178001

Group type: EXPERIMENTAL
Intervention: Physician training in shared decision-making (SDM) and electronic previsit reminders
Number of subjects: 466

Group type: COMPARATOR
Intervention: Reminders only (comparator group)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Physician training in SDM
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 466

Group type: COMPARATOR
Intervention: Comparator group
Number of subjects: 466
Study: 39178048

Group type: EXPERIMENTAL
Intervention: Burpees (T30: 32.2 kcals/min, T45: 40.7 kcals/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Jumping Jacks (T30: 23.1 kcals/min, T45: 22.8 kcals/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Push-ups (T30: 22.0 kcals/min, T45: 24.9 kcals/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Squat (T30: 19.9 kcals/min, T45: 23.2 kcals/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Single-leg Squat (T30: 19.8 kcals/min, T45: 21.2 kcals/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Forward Lunge (T30: 18.6 kcals/min, T45: 22.0 kcals/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plank (T30: 11.3 kcals/min, T45: 12.6 kcals/min)
Number of subjects: 10
Study: 39178051

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 67
Study: 39178062

Group type: EXPERIMENTAL
Intervention: Kettlebell swing (KBS) group (n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (CON; n = 20)
Number of subjects: 41
Study: 39178168

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy dressings (Prevena™ and PICO™)
Number of subjects: 2013

Group type: COMPARATOR
Intervention: Standard surgical dressings (control arm)
Number of subjects: 2013
Study: 39178272

Group type: EXPERIMENTAL
Intervention: Balika Bodhu intervention (empowerment and social norm based intervention)
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1120
Study: 39178291

Group type: EXPERIMENTAL
Intervention: Non-invasive transcutaneous auricular Vagus nerve stimulation (taVNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 39178369

Group type: EXPERIMENTAL
Intervention: VIGex-Hot
Number of subjects: 76

Group type: COMPARATOR
Intervention: I-Cold/Cold
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Baseline VIGex classification with ΔctDNA
Number of subjects: 76
Study: 39178640

Group type: EXPERIMENTAL
Intervention: Higher habitual degree of weight loss
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nutritional regulation during weight maintenance
Number of subjects: 62
Study: 39179000

Group type: EXPERIMENTAL
Intervention: Outpatient Palliative Care (OPC) - one visit a month for six months
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Outpatient Palliative Care (OPC)
Number of subjects: 603
Study: 39179051

Group type: EXPERIMENTAL
Intervention: Persistent airflow obstruction (PAO)
Number of subjects: 11886

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 11886

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 11886

Group type: EXPERIMENTAL
Intervention: Ever smoking
Number of subjects: 11886

Group type: EXPERIMENTAL
Intervention: Increased number of pack years
Number of subjects: 11886

Group type: EXPERIMENTAL
Intervention: Not being breastfed
Number of subjects: 11886

Group type: EXPERIMENTAL
Intervention: Ever diagnosis of asthma
Number of subjects: 11886
Study: 39179206

Group type: EXPERIMENTAL
Intervention: FIBCRO (sourdough-leavened croissant enriched with dietary fibers, 4.8 g/100 g)
Number of subjects: 32

Group type: COMPARATOR
Intervention: CONCRO (control croissant, dietary fibers 1.3 g/100 g)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: FIBCRO
Number of subjects: 32
Study: 39179207

Group type: EXPERIMENTAL
Intervention: Synbiotic (400 mg/100 mL GOS and L. reuteri DSM 17938)
Number of subjects: 82
Study: 39179252

Group type: COMPARATOR
Intervention: SBP <120 mm Hg (reference)
Number of subjects: 2608

Group type: COMPARATOR
Intervention: SBP 120-129 mm Hg
Number of subjects: 2608

Group type: COMPARATOR
Intervention: SBP 130-139 mm Hg
Number of subjects: 2608

Group type: COMPARATOR
Intervention: SBP ≥140 mm Hg
Number of subjects: 2608

Group type: COMPARATOR
Intervention: SBP ≥140 mm Hg in women
Number of subjects: 2608

Group type: COMPARATOR
Intervention: SBP ≥140 mm Hg in men
Number of subjects: 2608
Study: 39179255

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) including anti-PD-1 (79.3%), anti-PD-L1 (17.9%), combination of anti-PD-1 and anti-CTLA-4 (2.1%), anti-PD-1 with anti-VEGFR (0.7%)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 140
Study: 39179257

Group type: EXPERIMENTAL
Intervention: Ozoralizumab with methotrexate (MTX)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Ozoralizumab without MTX
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Ozoralizumab
Number of subjects: 521
Study: 39179363

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) and strength exercise for 12 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Moderately intensive physical activity, ≥150 min/week (Control Group)
Number of subjects: 87
Study: 39179458

Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin/100 mg sitagliptin fixed-dose combination (FDC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Individual component (IC) tablets of dapagliflozin and sitagliptin
Number of subjects: 46
Study: 39179638

Group type: EXPERIMENTAL
Intervention: S-MDMA (125 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: R-MDMA (125 mg and 250 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: S-MDMA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: R-MDMA (125 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: R-MDMA (250 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: R-MDMA
Number of subjects: 24

Group type: COMPARATOR
Intervention: S-MDMA, MDMA, R-MDMA
Number of subjects: 24
Study: 39179700

Group type: EXPERIMENTAL
Intervention: Propranolol (Group-1, n=110)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Propranolol (Group-2, n=129)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo (Group-3, n=111)
Number of subjects: 350
Study: 39179855

Group type: EXPERIMENTAL
Intervention: CyberRwanda facilitated arm (peer-led clubs plus tablet access)
Number of subjects: 6078

Group type: EXPERIMENTAL
Intervention: CyberRwanda self-service arm (self-guided access on tablets)
Number of subjects: 6078

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6078
Study: 39179863

Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with cisplatin and 5-fluorouracil (induction therapy)
Number of subjects: 47
Study: 39179948

Group type: EXPERIMENTAL
Intervention: Tazemetostat
Number of subjects: 20
Study: 39179982

Group type: EXPERIMENTAL
Intervention: Solution-Focused Brief Therapy (SFBT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 80
Study: 39180036

Group type: EXPERIMENTAL
Intervention: Virtual Diabetes Prevention Program (DPP) outreach
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Frequency of outreach by VA sites
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Virtual DPP
Number of subjects: 1473
Study: 39180108

Group type: EXPERIMENTAL
Intervention: Parent training program led by trained parent-teacher facilitator pairs
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 500
Study: 39180187

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with endocrine therapy (bicalutamide for 4 weeks and abiraterone for 2 years)
Number of subjects: 0
Study: 39180325

Group type: EXPERIMENTAL
Intervention: PF-06425090 vaccine (3 doses at 0, 1, and 6 months)
Number of subjects: 17535
Study: 39180326

Group type: EXPERIMENTAL
Intervention: Fecal microbiota, live-jslm (REBYOTA) administered rectally within 24-72h of antibiotic completion.
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Fecal microbiota, live-jslm (REBYOTA) administered rectally.
Number of subjects: 793
Study: 39180372

Group type: EXPERIMENTAL
Intervention: Head and Neck Patient Symptom Checklist (HNSC)
Number of subjects: 522
Study: 39180419

Group type: EXPERIMENTAL
Intervention: Monitoring for late-onset giant cell arteritis (GCA) using vascular ultrasonography and FDG-PET/CT scans during clinical visits at weeks 8 and 10, and follow-up at one year.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Baseline assessments including vascular ultrasonography and FDG-PET/CT scans.
Number of subjects: 62
Study: 39180711

Group type: EXPERIMENTAL
Intervention: Full Body Blue device (453 nm)
Number of subjects: 20
Study: 39180809

Group type: EXPERIMENTAL
Intervention: Duchenne muscular dystrophy (DMD) group
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Duchenne muscular dystrophy (DMD) group with distal site mutation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Typically developing children (control group)
Number of subjects: 68
Study: 39180960

Group type: EXPERIMENTAL
Intervention: Long-term fasting (LF)
Number of subjects: 40
Study: 39180989

Group type: EXPERIMENTAL
Intervention: SSRI + sarcosine
Number of subjects: 60

Group type: COMPARATOR
Intervention: SSRI + placebo
Number of subjects: 60
Study: 39181036

Group type: EXPERIMENTAL
Intervention: Modified malnutrition diagnosis (GLIM)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Low albumin concentration
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Low handgrip strength
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Low muscle radiodensity
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Combined parameters
Number of subjects: 269
Study: 39181037

Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation (2.0 g daily for 10 weeks)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HMB + EPA/DHA supplementation (3.0 g Ca-HMB daily for 10 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (soy + corn oil for EPA/DHA and maltodextrin for HMB)
Number of subjects: 46
Study: 39181168

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral agents
Number of subjects: 1152
Study: 39181206

Group type: EXPERIMENTAL
Intervention: Higher intake of green leafy vegetables (≥2.7 servings/week compared with none)
Number of subjects: 2697

Group type: EXPERIMENTAL
Intervention: Higher fish intake (≥ two 4-ounce servings/week compared with <2)
Number of subjects: 2697

Group type: EXPERIMENTAL
Intervention: Lutein/zeaxanthin (LZ) intake (≥2 mg/day compared with <2)
Number of subjects: 2697

Group type: EXPERIMENTAL
Intervention: Higher intake of ω-3 fatty acids (≥0.7 g/week compared with <0.7)
Number of subjects: 2697
Study: 39181214

Group type: EXPERIMENTAL
Intervention: Early PPG (measured 24-72 hours after TIPS)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Late PPG (measured 1 month after TIPS)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Immediate PPG (measured immediately after TIPS)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Targeting a post-TIPS PPG of 11-14 mmHg
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: PPG measured 24-72 hours after TIPS
Number of subjects: 466
Study: 39181325

Group type: EXPERIMENTAL
Intervention: Purity Independent Subtyping of Tumors (PurIST) algorithm using array-based NanoString nCounter Elements XT technology
Number of subjects: 74

Group type: COMPARATOR
Intervention: RNA sequencing (RNAseq)
Number of subjects: 74
Study: 39181422

Group type: EXPERIMENTAL
Intervention: Canakinumab (CAN) 3 mg/kg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Canakinumab (CAN)
Number of subjects: 57
Study: 39181426

Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) - 5:2 diet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) diet - 80% of the recommended calorie intake
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) - 5:2 diet (in patients with obesity)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) diet (in patients with obesity)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) - 5:2 diet (in patients without obesity)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) diet (in patients without obesity)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) diet
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (ICR) and Standard-of-Care (SOC) diet
Number of subjects: 72
Study: 39181485

Group type: EXPERIMENTAL
Intervention: POLARx cryoballoon (CB) ablation
Number of subjects: 429
Study: 39181556

Group type: EXPERIMENTAL
Intervention: Training with a racial justice framework
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training with a biomedical framework
Number of subjects: 0
Study: 39181597

Group type: EXPERIMENTAL
Intervention: Semaglutide 2·4 mg
Number of subjects: 17604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17604
Study: 39181887

Group type: EXPERIMENTAL
Intervention: TBI-223 (daily doses of 1200-2400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BPaL regimen (bedaquiline and pretomanid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 0
Study: 39182033

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) with personalized balance training (90 min/week)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (PR) alone
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) with balance training
Number of subjects: 258
Study: 39182045

Group type: EXPERIMENTAL
Intervention: suPAR > 5.1 ng/mL
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Combination of suPAR > 9.8 ng/mL, BMI < 29.3 kg/m2, PSI > 106.5
Number of subjects: 164
Study: 39182057

Group type: EXPERIMENTAL
Intervention: Mobilisation Initiative (MI) with formal education of clinical staff
Number of subjects: 596
Study: 39182135

Group type: EXPERIMENTAL
Intervention: Rad-Score developed using diffusion-weighted imaging (DWI)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Rad-Signature incorporating clinical parameters
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Rad-Score
Number of subjects: 356

Group type: COMPARATOR
Intervention: ESMO risk groups
Number of subjects: 356
Study: 39182137

Group type: EXPERIMENTAL
Intervention: Plastic stents (two 7-Fr double pigtail stents)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lumen-apposing metal stents (LAMS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plastic stents
Number of subjects: 80
Study: 39182315

Group type: EXPERIMENTAL
Intervention: Immediate mRNA-1273 vaccination
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Vaccine Declined
Number of subjects: 1198
Study: 39182330

Group type: EXPERIMENTAL
Intervention: Alirocumab plus statin therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 80
Study: 39182487

Group type: EXPERIMENTAL
Intervention: IV thrombolysis (IVT) in patients on oral anticoagulation
Number of subjects: 170

Group type: COMPARATOR
Intervention: IV thrombolysis (IVT) in patients without oral anticoagulation
Number of subjects: 170
Study: 39182573

Group type: EXPERIMENTAL
Intervention: Patients with obesity
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Patients without obesity
Number of subjects: 1370
Study: 39182589

Group type: EXPERIMENTAL
Intervention: RNS60
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39182617

Group type: EXPERIMENTAL
Intervention: Low-energy diet
Number of subjects: 104
Study: 39182655

Group type: EXPERIMENTAL
Intervention: Sirukumab 5 mg/kg IV on Day 1 plus standard of care
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo IV on Day 1 plus standard of care
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Sirukumab
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 39182827

Group type: EXPERIMENTAL
Intervention: Empathic Communication Skills (ECS) training
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual Care (waitlist control group)
Number of subjects: 96
Study: 39182847

Group type: EXPERIMENTAL
Intervention: Potatoes with meatballs (BFF)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Potatoes with plant protein (IMP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rice
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Meatballs
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Plant protein substitute
Number of subjects: 26
Study: 39182902

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (target home systolic blood pressure <120 mmHg)
Number of subjects: 1675

Group type: COMPARATOR
Intervention: Standard blood pressure control (home systolic blood pressure <135 mmHg)
Number of subjects: 1675
Study: 39183039

Group type: EXPERIMENTAL
Intervention: Osilodrostat, median dose 3.8 mg/day in Asian patients, 7.3 mg/day in non-Asian patients.
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Osilodrostat
Number of subjects: 210
Study: 39183095

Group type: EXPERIMENTAL
Intervention: Theory-based training program (5 sessions, 40 minutes each)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 92